Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)-a multicentre prospective study

被引:30
|
作者
Gemzell-Danielsson, K. [2 ]
Inki, P. [3 ]
Boubli, L. [4 ]
O'Flynn, M.
Kunz, M. [5 ]
Heikinheimo, O. [1 ]
机构
[1] Helsinki Univ Cent Hosp, Dept Obstet & Gynaecol, Helsinki 00029, Finland
[2] Karolinska Univ Hosp, Dept Obstet & Gynaecol, Stockholm, Sweden
[3] Bayer Schering Pharma AG, Global Med AffairsWomens Hlth, Berlin, Germany
[4] Hop Nord, Paris, France
[5] Bayer Schering Pharma AG, Dept Clin Stat, Berlin, Germany
关键词
bleeding profile; insertion; contraception; heavy menstrual bleeding;
D O I
10.1093/humrep/dep426
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The LNG-IUS has increasingly been used for contraception, treatment of menorrhagia and endometrial protection during hormone replacement therapy since mid-1990s. Thus, many women use the LNG-IUS consecutively. However, published data on the bleeding pattern regarding consecutive use of the LNG-IUS is scarce. We performed a prospective 15-month multicentre study on the bleeding profile, removal and insertion procedures and safety of the second LNG-IUS in fertile-aged women who had used their first LNG-IUS between 4 years 3 months and 4 years 9 months and who opted for the insertion of a second IUS immediately after removal of the first IUS. Bleeding data were reported descriptively starting from the last 90 days of the first IUS use and continuing for up to 1 year. Of the 234 subjects screened, 204 (87%) entered the trial. The median number of bleeding/spotting days during the last 90 days of the first LNG-IUS was 7 (25 and 75% percentiles 0 and 15). Due to bleeding associated with the insertion procedure, this increased to 8 days (4 and 18) during the first 90-day reference period, thereafter decreasing to 4 (0 and 10) days during the second to fourth reference periods. Only one expulsion and no pregnancies, pelvic inflammatory diseases or perforations occurred. A total of 12 subjects (5.9%) prematurely discontinued the study: five due to an adverse event and seven due to other reasons (inclusive of loss to follow-up). This study confirms the favourable bleeding profile and safety of consecutive use of the LNG-IUS.
引用
收藏
页码:354 / 359
页数:6
相关论文
共 50 条
  • [41] Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer Reply
    Trinh, Xuan-Bich
    Makar, Amin P.
    Buytaert, Guy
    Weyler, Joost
    van Dam, Peter A.
    [J]. FERTILITY AND STERILITY, 2009, 91 (04) : E6 - E6
  • [42] Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) - A systematic enquiry and overview
    Varma, Rajesh
    Sinha, Deepali
    Gupta, Janesh K.
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2006, 125 (01) : 9 - 28
  • [43] Comparison of Levonorgestrel-releasing Intrauterine System (LNG-IUS) against Laparoscopic Assisted Supracervical Hysterectomy (LASH) for menorrhagia treatment: An economic evaluation
    Laughton, Matthew
    Patel, Natasha Chandrakant
    Dawoodbhoy, Fatema Mustansir
    El-Ghrably, Salma
    Mahmud, Saheel
    [J]. JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2021, 50 (10)
  • [44] The effect of a levonorgestrel intrauterine system (LNG-IUS) on symptomatic endometriosis.
    Lockhat, FB
    Emembolu, J
    Konje, JC
    [J]. FERTILITY AND STERILITY, 2002, 77 (02) : S24 - S24
  • [45] Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in Human Immunodeficiency Virus (HIV) Infected Women - A Five-Year Follow-Up Study
    Heikinheimo, Oskari
    [J]. REPRODUCTIVE SCIENCES, 2010, 17 (03) : 88A - 88A
  • [46] Overcoming barriers to levonorgestrel-releasing intrauterine system placement: an evaluation of placement of LNG-IUS 8 using the modified Evolnserter® in a majority nulliparous population
    Gemzell-Danielsson, Kristina
    Apter, Dan
    Lukkari-Lax, Eeva
    Roth, Katrin
    Serrani, Marco
    [J]. CONTRACEPTION, 2017, 96 (06) : 426 - 431
  • [47] HISTOLOGICAL REGRESSION OF ENDOMETRIAL NEOPLASIA IN PATIENTS UNDER FERTILITY PRESERVATION TREATMENT WITH LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) plus SYSTEMIC PROGESTIN.
    Obregon, Fernanda
    Perez, Luis Oswaldo De la O.
    Diaz, Marisela Castaneda
    Jimenez, Sharey V. Vazquez, Sr.
    [J]. FERTILITY AND STERILITY, 2023, 120 (04) : E269 - E270
  • [48] Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5mg) after abortion for unintended pregnancy
    Caruso, Salvatore
    Cianci, Stefano
    Vitale, Salvatore Giovanni
    Fava, Valentina
    Cutello, Silvia
    Cianci, Antonio
    [J]. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2018, 23 (01): : 24 - 31
  • [49] Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas
    Grigorieva, V
    Chen-Mok, M
    Tarasova, M
    Mikhailov, A
    [J]. FERTILITY AND STERILITY, 2003, 79 (05) : 1194 - 1198
  • [50] Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs
    Jensen, Jeffrey T.
    Reinecke, Isabel
    Post, Teun M.
    Lukkari-Lax, Eeva
    Hofmann, Birte M.
    [J]. CONTRACEPTION, 2023, 120